MLN4924
Information
- Drug Name
- MLN4924
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00677170 | Completed | Phase 1 | Study of MLN4924 in Adult Patients With Nonhematologic Malignancies | April 2008 | December 2012 |
| NCT00722488 | Completed | Phase 1 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma | June 2008 | September 2013 |
| NCT00911066 | Completed | Phase 1 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia | June 2009 | October 2013 |
| NCT01011530 | Completed | Phase 1 | Dose Escalation Study of MLN4924 in Adults With Melanoma | December 2009 | January 2013 |
| NCT02122770 | Completed | Phase 1 | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors | April 1, 2014 | June 5, 2017 |
| NCT01814826 | Completed | Phase 1 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | April 10, 2013 | April 8, 2018 |
| NCT01862328 | Completed | Phase 1 | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | June 10, 2013 | May 21, 2018 |
| NCT01415765 | Withdrawn | Phase 1/Phase 2 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | July 15, 2011 | January 7, 2014 |
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Nedd 8 Activating Enzyme